Last reviewed · How we verify

Paclitaxel or docetaxel or irinotecan

Shanghai Runshi Pharmaceutical Technology Co., Ltd · Phase 3 active Small molecule

Paclitaxel or docetaxel or irinotecan is a Chemotherapy (taxane/camptothecin) Small molecule drug developed by Shanghai Runshi Pharmaceutical Technology Co., Ltd. It is currently in Phase 3 development for Non-small cell lung cancer, Breast cancer, Ovarian cancer.

These taxane and camptothecin chemotherapy agents stabilize microtubules or inhibit topoisomerase I to disrupt cell division and induce apoptosis in cancer cells.

These taxane and camptothecin chemotherapy agents stabilize microtubules or inhibit topoisomerase I to disrupt cell division and induce apoptosis in cancer cells. Used for Non-small cell lung cancer, Breast cancer, Ovarian cancer.

At a glance

Generic namePaclitaxel or docetaxel or irinotecan
SponsorShanghai Runshi Pharmaceutical Technology Co., Ltd
Drug classChemotherapy (taxane/camptothecin)
TargetMicrotubules (paclitaxel/docetaxel); Topoisomerase I (irinotecan)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Paclitaxel and docetaxel are microtubule-stabilizing agents that prevent microtubule depolymerization, disrupting mitotic spindle formation and cell cycle progression. Irinotecan is a topoisomerase I inhibitor that prevents DNA religation, causing DNA damage and cell death. All three are broad-spectrum chemotherapeutics used across multiple solid tumors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Paclitaxel or docetaxel or irinotecan

What is Paclitaxel or docetaxel or irinotecan?

Paclitaxel or docetaxel or irinotecan is a Chemotherapy (taxane/camptothecin) drug developed by Shanghai Runshi Pharmaceutical Technology Co., Ltd, indicated for Non-small cell lung cancer, Breast cancer, Ovarian cancer.

How does Paclitaxel or docetaxel or irinotecan work?

These taxane and camptothecin chemotherapy agents stabilize microtubules or inhibit topoisomerase I to disrupt cell division and induce apoptosis in cancer cells.

What is Paclitaxel or docetaxel or irinotecan used for?

Paclitaxel or docetaxel or irinotecan is indicated for Non-small cell lung cancer, Breast cancer, Ovarian cancer, Gastric cancer, Colorectal cancer.

Who makes Paclitaxel or docetaxel or irinotecan?

Paclitaxel or docetaxel or irinotecan is developed by Shanghai Runshi Pharmaceutical Technology Co., Ltd (see full Shanghai Runshi Pharmaceutical Technology Co., Ltd pipeline at /company/shanghai-runshi-pharmaceutical-technology-co-ltd).

What drug class is Paclitaxel or docetaxel or irinotecan in?

Paclitaxel or docetaxel or irinotecan belongs to the Chemotherapy (taxane/camptothecin) class. See all Chemotherapy (taxane/camptothecin) drugs at /class/chemotherapy-taxane-camptothecin.

What development phase is Paclitaxel or docetaxel or irinotecan in?

Paclitaxel or docetaxel or irinotecan is in Phase 3.

What are the side effects of Paclitaxel or docetaxel or irinotecan?

Common side effects of Paclitaxel or docetaxel or irinotecan include Neutropenia, Anemia, Thrombocytopenia, Peripheral neuropathy, Nausea/vomiting, Diarrhea.

What does Paclitaxel or docetaxel or irinotecan target?

Paclitaxel or docetaxel or irinotecan targets Microtubules (paclitaxel/docetaxel); Topoisomerase I (irinotecan) and is a Chemotherapy (taxane/camptothecin).

Related